Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
Condition:   COVID-19 Intervention:   Drug: Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI) Sponsor:   Aetion, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2022 Category: Research Source Type: clinical trials